Oxurion NV Stock

Equities

OXUR

BE0003846632

Biotechnology & Medical Research

Real-time Euronext Bruxelles 09:10:30 2024-05-24 am EDT 5-day change 1st Jan Change
0.0001 EUR 0.00% Intraday chart for Oxurion NV -50.00% -88.89%
Sales 2022 595K 644K Sales 2023 263K 285K Capitalization 2.92M 3.16M
Net income 2022 -31M -33.55M Net income 2023 -19M -20.56M EV / Sales 2022 20.6 x
Net Debt 2022 4.42M 4.79M Net Debt 2023 10.66M 11.54M EV / Sales 2023 51.6 x
P/E ratio 2022
-0.05 x
P/E ratio 2023
-0.08 x
Employees 20
Yield 2022 *
-
Yield 2023
-
Free-Float 90.01%
More Fundamentals * Assessed data
Dynamic Chart
1 day+100.00%
Current month+100.00%
1 month+100.00%
6 months-77.78%
Current year-77.78%
More quotes
1 week
0.00
Extreme 0.0001
0.00
1 month
0.00
Extreme 0.0001
0.00
Current year
0.00
Extreme 0.0001
0.00
1 year
0.00
Extreme 0.0001
0.01
3 years
0.00
Extreme 0.0001
2.63
5 years
0.00
Extreme 0.0001
6.78
10 years
0.00
Extreme 0.0001
18.33
More quotes
Managers TitleAgeSince
Chief Executive Officer - Dec. 27
Corporate Officer/Principal - 08-05-31
Members of the board TitleAgeSince
Director/Board Member 64 23-05-01
Director/Board Member 58 Dec. 27
Director/Board Member - 23-05-01
More insiders
Date Price Change Volume
24-05-24 0.0001 0.00% 155 711 582
24-05-23 0.0001 0.00% 10,362,800
24-05-22 0.0001 -50.00% 263,492,000
24-05-21 0.0002 +100.00% 1,405,160
24-05-20 0.0001 -50.00% 734,229,300

Real-time Euronext Bruxelles, May 24, 2024 at 04:49 am EDT

More quotes
Oxurion NV is a biopharmaceutical company developing next generation therapies, designed to improve and better preserve vision in patients with retinal disorders including Geographic Atrophy (GA), the leading cause of vision loss in elderly people worldwide. Oxurion NV is aiming to build the leading global franchise in the treatment of Age-related macular degeneration (AMD), based on the successful clinical development of its two novel therapeutics: THR-149, a plasma kallikr ein inhibitor being developed as a potential new standard of care for AMD patients who respond sub-optimally to anti-VEGF therapy, and THR-687, a pan-RGD integrin inhibitor, initially being developed as a potential new standard of care for all AMD patients.
Calendar
More about the company

Annual profits - Rate of surprise